In late 2017, the first human Phase I/II clinical trial of NIR-PIT using cetuximab-IR700 (RM-1929) targeting the EGFR for the treatment of patients with inoperable head and neck squamous cell carcinoma (HNSCC) was successfully completed (https://clinicaltrials.gov/ct2/show/NCT02422979). Here, EGFR is linked to head and neck squamous cell carcinoma.